Behnsen et al., 2013 - Google Patents
Probiotics: properties, examples, and specific applicationsBehnsen et al., 2013
View PDF- Document ID
- 7597740437790446007
- Author
- Behnsen J
- Deriu E
- Sassone-Corsi M
- Raffatellu M
- Publication year
- Publication venue
- Cold Spring Harbor perspectives in medicine
External Links
Snippet
Probiotics are beneficial components of the microbiota that have been used for centuries because of the health benefits they confer to the host. Only recently, however, has the contribution of probiotics to modulation of immunological, respiratory, and gastrointestinal …
- 230000000529 probiotic 0 title abstract description 54
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Micro-organisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Micro-organisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/025—Enterobacteriales, e.g. Enterobacter
- A61K39/0291—Yersinia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Behnsen et al. | Probiotics: properties, examples, and specific applications | |
| Anjana et al. | Bacteriocin-producing probiotic lactic acid bacteria in controlling dysbiosis of the gut microbiota | |
| Ducarmon et al. | Gut microbiota and colonization resistance against bacterial enteric infection | |
| Vonaesch et al. | Pathogens, microbiome and the host: emergence of the ecological Koch's postulates | |
| Mathipa et al. | Probiotic engineering: towards development of robust probiotic strains with enhanced functional properties and for targeted control of enteric pathogens | |
| Liévin-Le Moal et al. | Anti-infective activities of lactobacillus strains in the human intestinal microbiota: from probiotics to gastrointestinal anti-infectious biotherapeutic agents | |
| AU2016278070B2 (en) | Compositions comprising bacterial strains | |
| Lutgendorff et al. | The role of microbiota and probiotics in stress-induced gastrointestinal damage | |
| Oelschlaeger | Mechanisms of probiotic actions–a review | |
| Sonnenborn et al. | The non-pathogenic Escherichia coli strain Nissle 1917–features of a versatile probiotic | |
| O’Callaghan et al. | Lactobacillus: Host–microbe relationships | |
| Kampmeier et al. | The 2011 German enterohemorrhagic Escherichia coli O104: H4 outbreak—The danger is still out there | |
| Corcionivoschi et al. | Probiotics-identification and ways of action | |
| Tsai et al. | Immunomodulating activity of Lactobacillus paracasei subsp. paracasei NTU 101 in enterohemorrhagic Escherichia coli O157H7-infected mice | |
| Pang et al. | Xylo‐oligosaccharide alleviates Salmonella induced inflammation by stimulating Bifidobacterium animalis and inhibiting Salmonella colonization | |
| Gu et al. | Bacteriocins: Curial guardians of gastrointestinal tract | |
| Schultz et al. | Escherichia coli Nissle 1917 | |
| JP2024529325A (en) | Compositions and Methods for Treating Disease II | |
| El-Deeb et al. | Probiotics and GIT diseases/stomach ulcer | |
| Van Zyl | Gastrointestinal persistence of the probiotic bacteria Lactobacillus plantarum 423 and Enterococcus mundtii ST4SA, and their anti-listerial activity | |
| Fujiya et al. | Novel perspectives in probiotic treatment: the efficacy and unveiled mechanisms of the physiological functions | |
| Even et al. | Lactic acid bacteria to modulate virulence expression in pathogenic bacteria | |
| Lönnermark | Lactobacilli in the normal microbiota and probiotic effects of Lactobacillus plantarum | |
| Steidler et al. | In situ delivery of therapeutic proteins by recombinant Lactococcus lactis | |
| Villa et al. | Fecal Matter Implantation as a Way to Fight Diarrhea-Causing Microorganisms |